ARTICLE / CLIENT ALERT
FDA Gives Companies a New Way to Fight Misinformation
July 30, 2024
Read time: 8 min
Misinformation shared by independent third parties presents a significant public health concern because it can lead patients and healthcare providers to forgo treatments that are safe and effective or choose treatments that are not. Such misinformation is especially harmful when it is shared by an internet user with a large following or someone who holds a position of trust, and when the misinformation relates to medical products that treat or prevent serious or life-threatening diseases. However, industry players have been limited in what they can legally say about their medical products, curtailing the ability to address harmful false statements.
On July 8, 2024, the US Food and Drug Administration (FDA) issued draft guidance on how to effectively address the growing problem of online misinformation about medical products, titled Addressing Misinformation About Medical Devices and Prescription Drugs: Questions and Answers. The new draft guidance replaces earlier draft guidance from 10 years ago and proposes to grant leeway to companies when addressing third-party misinformation about or related to their cleared or approved medical products.
Under the new draft guidance, companies may choose to address such misinformation with a “tailored responsive communication,” which, if published in line with the FDA’s guidance, will not be subject to traditional promotional marketing requirements. For example, if an independent third party posts on their blog that a new prescription drug (Drug X) has been approved to treat non-small cell lung cancer but according to Drug X’s Prescribing Information it is a second-line treatment approved for certain patients with non-small cell lung cancer who have unsuccessfully tried a chemotherapy regimen containing platinum, then the blogger’s post is false, inaccurate and/or misleading because it omits material facts regarding the full indication for Drug X. Therefore, Drug X’s manufacturer may post a response to address the misinformation about Drug X’s indication if the company’s post comports with the guidance’s requirements (outlined in more detail below).
The revised draft guidance is open for public comment until September 9, 2024.
The draft guidance focuses on a firm’s voluntary responses to internet-based misinformation created or disseminated by independent third parties about or related to the firm’s approved or cleared medical products. For purposes of the guidance, “misinformation” is “implicit or explicit false, inaccurate, or misleading representations of fact about or related to the firm’s approved/cleared medical product” and an expansive list of statements meeting this definition is included. “Independent third party” is a person or entity that, in communicating about a firm’s approved or cleared medical product, is not acting on behalf of that firm.
The FDA splits its recommendations, presented in Q&A format, into two categories. The first category refers to recommendations for tailored responsive communications, which are a company’s voluntary internet-based communications that identify and address online third-party misinformation about the company’s approved or cleared medical products. It outlines an enforcement policy for these types of industry communications, explaining that the FDA will not enforce marketing requirements usually applicable to such communications if a company issues them in line with the guidance.
The second category concerns permissible “general medical product communications,” which are the existing ways companies may communicate about their approved or cleared medical products. This includes online communications about a product and non-internet communications channels such as sales aids and TV advertisements. Because they are not included in the reduced enforcement policy for tailored responsive communications, these types of communications must comply with all applicable FDA requirements and other relevant regulations. However, a company addressing misinformation in such a communication does not create special considerations regarding the application of FDA enforcement policies as these types of general communications are already permitted.
Tailored Responsive Communications
As stated above, the enforcement policy outlined in the guidance applies to tailored responsive communications that identify and address misinformation that is (1) about or related to the company’s approved or cleared medical product, (2) in an internet-based communication, and (3) created or disseminated by an independent third party. Of note, the first criterion does not require that the product be mentioned by name. The misinformation may refer to an entire class of drugs or devices.
The draft enforcement policy provides that if a company issues a tailored responsive communication in accordance with the guidance in this subsection, the FDA does not intend to enforce applicable requirements for promotional labeling and advertising or post-marketing submission of promotional communications. Also, if a company issues a tailored responsive communication addressing misinformation that its product should be used for an unapproved use and the communication follows the guidance in this subsection, the FDA does not intend to use such communication as evidence of a new intended use.
The draft enforcement policy has several limitations. First, it does not extend to a company’s responses to statements describing opinions or value statements about an approved or cleared medical product. Additionally, it does not apply to a company’s responses to representations about an individual patient’s experience using a company’s product, whether made by that individual or others, unless the statements include misinformation as defined in the guidance.
In addressing independent third-party misinformation, the guidance states that the company should clearly identify both the specific post or communication and the misinformation. When a company identifies misinformation that is widespread, it should at least clearly identify one statement that contains the misinformation to be addressed. Overall, a company should ensure that the information in its tailored responsive communication is (1) truthful and accurate, (2) scientifically sound, (3) directly relevant and responsive to the identified misinformation, and (4) limited to the information necessary to address the identified misinformation as well as any recommended disclosures to help the public understand the context of the response.
Additional recommended disclosures include a mechanism for obtaining a copy of the current FDA-required labeling, the date the company’s tailored responsive communication is posted (if a date is not automatically generated) and a disclosure that it is being shared by the company. Moreover, if a company wishes to address misinformation that its product should be used for an unapproved use, the FDA recommends that it include a statement identifying the unapproved use(s) and noting that the unapproved use(s) of the product has not been approved by the FDA and that the safety and effectiveness of the product for that use has not been established. Such recommended disclosures should be presented clearly and prominently.
The FDA recommends that companies prioritize addressing misinformation that has current relevance (e.g., it is trending or actively spreading online) and is being spread by independent third parties with large followings or who hold positions of trust. Regardless of where the misinformation first appeared, companies may post tailored responsive communications to different or additional online forums or social media platforms but should ensure that other platforms allow the entirety of the original post to be displayed.
General Medical Product Communications
The guidance also addresses a second category of corrective firm communications: existing avenues companies can utilize to address misinformation other than tailored responsive communications. Such general medical product communications fall outside of the reduced enforcement policy and therefore must comply with applicable FDA regulations.
This includes promotional communications that provide information about an approved or cleared product’s safety and effectiveness. In such communications, companies may decide whether to address misinformation implicitly, without directing attention to that misinformation, or call out the misinformation expressly. Companies may also choose to share promotional communications in a variety of settings, internet-based or not, as they retain the flexibility to direct their communication approaches. For example, a company may enlist healthcare providers to help reach that audience, reach the general public via a radio advertising campaign, work with an influencer to convey the company’s message in internet-based settings, or any combination of these avenues as long as the promotional communication complies with the pertinent FDA requirements, including promotional labeling, advertising and information on unapproved or uncleared uses.
If you are interested in submitting comments, or if you have questions about the new draft guidance, please contact one of the authors or any other member of McDermott’s Food, Drug & Medical Device Regulatory Practice Group.
Henny Schlaeger, a summer associate in the Washington, DC, office, also contributed to this article.

Legal Lens on the Unified Patent Court | July 2024
ARTICLE
Legal Lens on the Unified Patent Court | July 2024
July 2024
Read time: 2 min
The Unified Patent Court (UPC) is revolutionizing the way patents are enforced in Europe, and McDermott’s intellectual property team is here to help you navigate this dynamic landscape. Our Legal Lens on the Unified Patent Court newsletter is designed to keep patent holders and legal departments well-informed. And with an on-the-ground team in Germany, France, the United Kingdom and the United States, we offer a unique cross-border perspective.

UK Compliance Update: FCA Rules Will Allow CSA-Style Payments for Research From 1 Aug. 2024
ARTICLE / CLIENT ALERT
UK Compliance Update: FCA Rules Will Allow CSA-Style Payments for Research From 1 Aug. 2024
July 30, 2024
Read time: 11 min
The UK Financial Conduct Authority (“FCA”) has released the final rules on the Payment Optionality for Investment Research in its PS 24/9.[i] The FCA rules refer to this new research payment structure as “joint payments for third-party research and execution services”; in fact, it is based on a commission sharing arrangement (“CSA Option”) combined with detailed procedural and operational safeguards, including budgeting, valuation and client disclosure obligations. Managers who intend to take up the CSA Option will need to ensure the procedural safeguards are appropriately implemented in written compliance policies, CSA agreements or similar, client agreements and periodic client reporting, as appropriate.
The CSA Option will be welcome news for UK managers who buy investment research from US brokers. Maintaining some of the existing US research relationships has proven challenging for UK managers since the expiration, in July 2023, of the SEC no-action relief[ii] allowing US broker-dealers to receive separate payments for research without the need to register under the Investment Advisers Act of 1940, as amended (“Advisers Act”). The CSA Option will be equally welcome by global asset management groups that have had to adopt different research payment structures for their investment teams depending on their location. Managers whose clients refuse to pay for research as a separate charge but are open to soft-dollar or CSA arrangements meeting the conditions of Section 28(e)[iii] may also wish to consider the CSA Option.
Background
In 2018, FCA rules applicable to so-called “inducements” were modified to give effect to MiFID II “unbundling” reforms. Research is considered a type of inducement, or benefit which the manager receives in connection with the portfolio management services it provides to its clients. The MiFID II reforms required payments for research to be made separately from execution. The policy objectives of the MiFID II reforms were to manage conflicts of interest, improve accountability over costs passed to clients, and improve price transparency for both research and execution services.
Under the current rules, FCA-regulated managers are required either to pay for research themselves from their own resources (a so-called, “P&L model”) or obtain their clients’ agreement to a separate research charge and pay brokers via a separate “Research Payment Account” (“RPA”). 2023 saw the publication of the Investment Research Review (“IRR”) commissioned by the HM Treasury as part of the post-Brexit strive to boost the competitiveness of UK markets. The IRR concluded that the unbundling rules had an adverse impact on the investment research coverage in the UK, and by extension, a potentially negative impact on the amount of funding available to UK companies. The IRR’s other findings highlighted that unbundling reduced UK asset managers’ access to global investment research, placing them at a competitive disadvantage internationally. The final rules in PS 24/9 follow an earlier FCA consultation[iv] (“CP 24/7”)) and give effect to some of the recommendations of the IRR.
This CSA Option will exist alongside the RPA and P&L options. In a coordinated move, similar changes to the research unbundling rules are expected to be introduced by EU legislators as part of the MiFID II review. These changes will apply to EU-based investment firms and are expected to offer greater flexibility to global firms with operations in the EU in the future.
Documentation and Procedural Requirements Applicable to the CSA Option
Managers wishing to use the CSA Option, must comply with the following procedural and client disclosure requirements set out in COBS 2.3B of the FCA Hadbook:
- Implement a written policy on CSA payments. Managers must implement a written policy describing the firm’s approach to joint payments addressing governance, decision-making and controls over CSA payments (including those detailed below). In most cases, this will necessitate updates to existing research policies designed to comply with the RPA or P&L optionalities. Managers will separately need to ensure that their best execution analysis does not treat provision of research services as an execution factor.
- Stipulate methodology and structure for research payments. Managers must establish arrangements with their executing brokers which stipulate the methodology for how research costs are calculated and identified separately. Managers must also establish a structure for the allocation of research payments between the different research providers, including executing brokers and any independent research providers (“IRPs”). The separately identifiable research charges may only be used to purchase research.Although (unlike the CP 24/7 consultation version), the final rules no longer require there to be a written agreement with the executing brokers and any IRPs setting out the chargingmethodology and allocation structure, it is likely that these structures and methodology would in practice need to be documented in a CSA-style agreement.
- Administration. Administration of the CSA Option can be delegated to a third-party administrator; however, the manager will remain responsible for the operation of such accounts and ensuring that the CSA Option does not interfere with the manager’s obligations to comply with the FCA rules on inducements. In particular, the manager must ensure that the reconciliation and reporting for the CSA Option is undertaken with an appropriate frequency to allow effective monitoring and risk management from unspent surplus amounts and research provider concentrations of these surplus amounts. The FCA statements made in PS 24/9 imply that the costs of administering a CSA cannot be passed on to a client.
- Budgeting and allocation of costs among clients. A budget for the purchase of research using the CSA Option must be set at least on an annual basis and must be based on the manager’s expectations for the need for third-party research. The research budget must not be linked to the expected volumes or value of transactions. Unlike the consultation draft, managers are not required to set a budget at the level of a client or investment strategy, but instead will have flexibility to adopt the approach they consider appropriate to their investment process, products, services and clients, subject to the overall obligation to ensure that the outcome is fair, such that the relative costs incurred by clients are commensurate with relative benefits received.
- Valuation and price benchmarking. At least on an annual basis, managers using the CSA Option must assess the value, quality and their use of research and its contribution to the investment decision-making process. This assessment must include an element of benchmarking with comparable services to ensure that the amount of research charges passed on to the clients is reasonable.
- Client disclosures. As under the existing RPA requirements, managers utilising the CSA Option must disclose to their clients (i) the firm’s use of the CSA option, including, where relevant, how the use of joint payments may be combined with the RPA or P&L optionalities; (ii) the key features of the firm’s research policy; (iii) the expected annual costs to the client based on the expected research budget or the actual costs for the prior period, as appropriate, on an ex ante basis; (iv) the actual total cost of research incurred by the client, annually, as part of an ex post reporting on costs and charges; and (v) key information on the types of benefits and services received from research providers (measured by total amounts paid) and the types of research providers (e.g. executing brokers vs IRPs) from whom such services are purchased. The disclosures must be communicated in a way which is clear, fair and not misleading. If a previously notified research budget is being exceeded, the client should be notified as soon as reasonably practicable, for example, as part of a firm’s next periodic reporting on costs and charges.
Other Changes
Other notable rule changes in PS 24/9 are:
- Short-term trading commentary and advice linked to trade execution have been added to the list of acceptable minor non-monetary benefits (“MNMB”) which means that UK managers are permitted to receive this type of service from their executing brokers without separately paying for it. This change is the result of the FCA’s engagement with market participants which highlighted challenges facing UK asset managers receiving research from US broker-dealers.
- The current rules classifying investment research on small and medium enterprises with a market capitalisation below £200 million (SMEs) as MNMBs has been deleted. Based on the FCA’s assessment, this option has had little take-up and, accordingly, was deemed redundant. The provisions classifying corporate access in relation to SMEs as an acceptable MNMB have been retained.
Application to UK AIFMs
The MIFID II research unbundling rules are applied to non-MIFID managers, such as alternative investment fund managers (AIFMs) and UCITS management companies through the FCA rules in COBS 18 Annex I. The final rules set out in PS 24/9 have not so far been mirrored in corresponding amendments to COBS 18 Annex 1. The FCA intends to consult separately on the required changes to COBS 18 Annex I. It is likely that the differences between COBS 2.3B and the rules in COBS 18 Annex I will be confined to modifying the client disclosure obligations as appropriate for fund clients.
Corporate Access and Other Services Not Covered in PS 24/9
The FCA noted in PS 24/9 that it had received feedback on several points that did not directly relate to the policy changes proposed in CP 24/7. As such, PS 24/9 did not address the current status of corporate access services (apart from SME corporate access above) and the possibility of using the CSA Option to pay for corporate access services. Other points raised by respondents to CP 24/7 included the rules on research trials, status of FICCs and macro research, and the VAT treatment of research payments under the CSA Option. The FCA has made no comment on whether these points may be clarified through future consultations or guidance.
US Market Considerations
While the CSA Option should prove useful for UK Managers who buy investment research from US brokers, some potential issues will need to considered.
For instance, certain US brokers do not identify an explicit price for their proprietary research; rather, the manager receiving such proprietary research makes an independent assessment of the value of such research in relation to the commissions paid. As the CSA Option contemplates that research being obtained will have an explicit price, certain proprietary research may not be available under the CSA Option absent a change in brokers’ practices.
Further, while the UK Manager’s research budget may not be linked to expected trade volumes, funding may be achieved through payments linked to executions. Although many US brokers are accustomed to arrangements in which a defined portion of a commission is recorded as part of a manager’s “soft dollar balance”, that is due, in part, to the payment being characterized as a commission rather than a separate payment that could trigger a registration obligation under the Advisers Act. US brokers will need to assess the nature of research payments made under the CSA Option to ensure they do not raise registration concerns under the Advisers Act.
Separately, UK managers should consider the manner in which CSA balances are maintained by US brokers. Unlike customer cash, US brokers are not required to reserve against soft dollar balances, nor do US brokers necessarily maintain such balances in a segregated account. This may require additional negotiation around custody arrangements when engaging US brokers and CSA administrators.
Authored by Anna Maleva Otto and William J. Barbera.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
[i] FCA Policy Statement (PS 24/9): Payment Optionality for Investment Research
[ii] Statement on the Expiration of the SEC Staff No-Action Letter re: MIFID II
[iii] Section 28(3) of the Securities and Exchange Act 1934.
[iv] FCA Consultation (CP 24/7): Payment Optionality for Investment Research
This communication is issued by Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2024 Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

Pennsylvania expands access to ready-to-drink Cocktails
ARTICLE
Pennsylvania expands access to ready-to-drink Cocktails
Jul 26, 2024
Read time: 3 min
On July 17, 2024, Pennsylvania Governor Josh Shapiro signed SB 688 into law, expanding the number of available outlets that can sell ready-to-drink cocktails (RTDs) across the state.
The new law defines “Ready-to-drink cocktails” as “beverage[s], composed in part of distilled liquor … premixed and packaged in original containers by the manufacturer, containing not more than sixteen ounces … The term shall include any beverage consisting of at least one-half of one per centum, but not greater than twelve and one-half per centum, alcohol by volume.” Notably, this term does not encompass beer, malt or wine-based RTD beverages.
Explaining the intent behind the bill, sponsor Senator Mike Regan, in a February 17, 2023, memo, cited the recent growth and overall popularity of the RTD category as the reason why RTD beverages deserve to be treated differently from other liquor-based products.
Prior to the new law, liquor-based RTDs could only be sold through state-run stores, where they compete for limited shelf and cooler space that is not commensurate with their market share. Spirits and all products containing spirits had to be sold by in-state manufacturers and out-of-state vendors to the Pennsylvania Liquor Control Board. The board would then sell to liquor-licensed retailers, such as restaurants and bars, and to its state liquor stores. As a result, consumers would have to purchase RTDs in the same manner they would purchase higher ABV spirit products at a state-run store.
With SB 688’s enactment, Pennsylvania now allows for these spirits-based RTDs to be sold either through the board state-store system or through the state’s independently licensed beer network with the acquisition of an additional permit. Notably for manufacturers – both in-state and out-of-state – Pennsylvania’s franchise laws that cover Pennsylvania beer distribution do not extend to RTDs.
Before buying RTDs for resale, retailers and distributors will need to acquire a new type of permit called a “Ready-to-Drink Cocktail Permit.” Retailers will be able to purchase RTDs from state-run stores (as they do currently) and also from in-state limited distilleries. Consumers will be able to purchase RTDs from the retailers who have acquired the “Ready-to-Drink Cocktail Permit,” from state stores, from in-state distilleries, and from distributors and importing distributors.

Labor Markets in the Focus of European Competition Law
ARTICLE
Labor Markets in the Focus of European Competition Law
Jul 25, 2024
Read time: 5 min
In May 2024, the European Commission published a Competition Policy Brief classifying certain agreements related to labor markets as serious antitrust infringements. According to the Commission, so-called wage-fixing and no-poach agreements can only be justified in exceptional cases. The Brief follows the first unannounced inspections by the Commission concerning labor market agreements in Germany and Spain in the online meal ordering and delivery industry. It is vital that companies operating in Europe focus on educating their recruiting and human resources departments on antitrust rules to avoid severe fines.
LABOR MARKETS ON THE AGENDA
The Commission’s Competition Policy Brief could be interpreted as a warning for companies exposed to tight labor markets: Restrictive labor market agreements between competitors will be taken as seriously as price-related cartels. Companies must also bear in mind that competitors for labor are not limited to those companies with which they compete to sell products or services. It is sufficient that they compete for the same employees.
Given that restrictions on competition in labor markets mainly affect national markets, the main investigators will be (and already are) national competition authorities.
WHAT AGREEMENTS ARE CAUGHT
The following types of labor market agreements are considered potentially problematic:
- No-poach agreements: In some cases, employers (in writing or orally) agree not to steal employees from each other. Such agreements can take different forms: In the case of nonsolicitation or no-cold-calling agreements, companies agree not to actively approach the other companies’ employees with a job opportunity. More far-reaching are no-hire agreements, i.e., companies agree not to hire (actively or passively) employees of other parties to the agreement. As a matter of principle, all forms of no-poach agreements in the Commission’s view constitute market sharing (supply-source sharing) within the meaning of Article 101(1)(c) of the Treaty on the Functioning of the European Union (TFEU) and therefore form a competition risk to be sanctioned.
- Wage-fixing agreements: Sometimes, employers agree to fix wages or other types of compensation or benefits for their respective employees. The Commission considers these agreements akin to price fixing within the meaning of Article 101(1)(a) of the TFEU.
The Commission does acknowledge that no-poach agreements may pursue a legitimate objective by incentivizing companies to invest in training their own employees without fearing that they would be later lured away by competitors, and by preventing employees from taking non-patent intellectual property rights (such as trade secrets) to competitors. However, both types of agreements “reveal a sufficient degree of harm to competition” such that the Commission does not see a need to examine their effects. Due to their alleged negative impact on employees’ wages, firm productivity and innovation, they are regarded “by their very nature” as harmful.
The above does not apply, however, to collective bargaining agreements between organizations representing employers and employees, which are explicitly outside the scope of the Commission’s Competition Policy Brief. The Court of Justice of the European Union (CJEU) recognized that certain restrictions of competition are inherent in collective agreements, which are intended, by their nature and purpose, to improve working conditions (including pay).
ACTION ITEMS
The Commission will consider the above-mentioned agreements as competition law violations without carrying out a detailed assessment of their actual effects. The analysis of potential pro-competitive effects will most likely be limited to what the Commission considers strictly necessary.
Only in rare scenarios will such labor market restrictions meet the requirements either to qualify as so-called ancillary restraints or to be exempted under Article 101(3) of the TFEU. To be accepted as an ancillary restraint, as held earlier by the CJEU in its Mastercard judgment and referenced by the Commission with regard to labor markets, a restriction must be proportionate, directly linked and objectively necessary for the implementation of the nonrestrictive business agreement (such as a cooperation or joint venture). In other words, the parties to the agreement must prove that there are no other less restrictive means available to serve the legitimate business rationale as effectively as the no-poach agreement and that, given the nature of the agreement and the characteristics of the market in question, another company in that situation (objectively) would not have joined the business agreement without a no-poach agreement. A good example of how these requirements could be assessed in practice is demonstrated by a complaint handled by the Croatian competition authority concerning the IT sector.
In this regard, EU law may be more confining than rule of reason analysis under US law, where a no-poach or no-hire provision that is reasonably tailored in scope and duration to protect a legitimate risk arising from a business agreement could be permissible.
Companies should therefore pursue less restrictive ways to retain employees or protect business secrets (e.g., nondisclosure agreements, obligations to stay with an employer for a minimum amount of time or to repay proportionate training costs, gardening leaves). Another possibility could be the execution of noncompete agreements – or clauses – with a company’s own employees. As the Commission acknowledges, such agreements are not made between undertakings and therefore are generally outside the scope of EU antitrust law. A company must nevertheless ensure that such noncompete clauses comply with national labor laws.
Regarding compliance measures, it is essential to educate not only salespeople but also human resources and recruiting departments on what constitutes an antitrust infringement. Further, no-poach agreements used in connection with M&A due diligence and negotiations, cooperation agreements or joint venture situations should also be reviewed in detail to ensure they do not go beyond what is permitted.

SEC Faces Headwinds in SolarWinds Cybersecurity Litigation, but Public Companies and CISOs Still Under Scrutiny
ARTICLE / CLIENT ALERT
SEC Faces Headwinds in SolarWinds Cybersecurity Litigation, but Public Companies and CISOs Still Under Scrutiny
July 24, 2024
Read time: 13 min
On July 18, 2024, Judge Paul A. Engelmeyer in the US District Court for the Southern District of New York issued a 107-page opinion dismissing most of the claims against software company SolarWinds and its chief information security officer (CISO) in an enforcement action brought by the US Securities and Exchange Commission (SEC) for disclosures related to cybersecurity and a 2020 Russia-linked cyberattack known as SUNBURST. There are multiple takeaways from the opinion for public company counsel, CISOs and the defense bar:
- The internal controls statute in the Securities and Exchange Act of 1934 (Exchange Act) is limited to accounting controls.
- With investment in reasonably designed and executed policies and procedures, isolated process lapses do not support disclosure-control violations.
- In court, the SEC will face difficulty attempting to second-guess otherwise robust incident disclosures.
- Courts may not view risk disclosures as a catch-all hook for securities fraud claims.
- Notwithstanding the defense victories, serious risks remain for companies, their CISOs and other officers.
Given the continued enforcement interest in this space, as well as new cybersecurity reporting rules, issuers should remain diligent and invest in process and controls. That effort requires careful coordination between securities practitioners and cybersecurity experts.
The Facts
SolarWinds is a public company that designs and sells IT management software. In late 2019, threat actors gained access to the company’s system and inserted malicious code into a SolarWinds platform, creating a “backdoor into the network environments” of 18,000 SolarWinds customers, including federal and state government agencies and more than 1,500 publicly traded companies, banks, broker-dealers, accounting firms and other SEC-regulated entities. Threat actors then engaged in a series of cyberattacks targeting SolarWinds’ platform and customers, culminating in a large-scale cyberattack known as SUNBURST in December 2020.
In 2023, the SEC filed a litigated action against SolarWinds and its CISO alleging:
- SolarWinds made false and misleading public statements about its cybersecurity.
- SolarWinds made materially false statements in its Form 8-K disclosures following the SUNBURST attack, including by omitting previous cybersecurity incidents from the disclosure.
- SolarWinds’ deficient internal cybersecurity controls violated Exchange Act Section 13(b)(2)(B)’s requirement to “devise and maintain a system of internal accounting controls.”
Given the SEC’s aggressive pursuit of a corporate victim of a cyberattack perpetrated by a nation-state adversary and its decision to charge a CISO, the SolarWinds action has been closely watched.
The Court’s Decision
(1) Fraud Claims Based on Public Disclosures
The SEC pursued securities fraud claims under Section 10(b) of the Exchange Act, Rule 10b 5, and Section 17(a) of the Securities Act of 1933. The securities fraud claims were brought under two theories: misrepresentation liability and scheme liability. Generally speaking, misrepresentation liability requires the SEC to show that, in connection with the purchase or sale of a security, the defendant, acting with scienter, made a material misrepresentation or misleading omission. Scheme liability requires showing that the defendant committed a manipulative or deceptive act in furtherance of the alleged scheme to defraud, with scienter.
Evaluating a motion to dismiss, the district court held that the SEC sufficiently pleaded securities fraud under both the misrepresentation and scheme liability theories as to a security statement (Security Statement) that described SolarWinds’ cybersecurity practices and was published on the SolarWinds website and disseminated to its customers. The court dismissed the securities fraud claims as to the other public statements, holding they were too generalized to mislead investors:
- Security Statement: The court concluded that the SEC adequately alleged that the Security Statement included material misrepresentations that SolarWinds had, inter alia, strong password protections and maintained good access controls. The court found, however, that “the company fell way short of even basic requirements of corporate cybersecurity health. Its passwords – including for key products – were demonstrably weak and the company gave far too many employees unfettered administrative access and privileges, leaving the door wide open to hackers and threat actors.” Importantly, the court rejected the defendants’ suggestion that a statement could not be actionable because it was directed at customers, not investors. According to the court, it is well established that false statements on public websites can sustain securities fraud liability. The court also imputed scienter from the CISO to SolarWinds, noting that the CISO was privy to internal information contradicting the Security Statement’s representations both as to the company’s access controls and compliance with the password policy, but nevertheless approved and disseminated the Security Statement.
- Cybersecurity Risk Disclosure: Significantly, the court dismissed the SEC’s fraud claims based on SolarWinds’ cybersecurity risk disclosures made in its 2018 Form S-1 registration statement and incorporated by reference in later SEC filings. The SEC argued the disclosures contained boilerplate language that concealed the gravity of the cybersecurity risks that SolarWinds faced, and that SolarWinds had a duty to update its risk disclosure in light of the cybersecurity incidents preceding SUNBURST. The court dismissed the claims, finding that the disclosure detailed “unique risks” that warned investors about the serious threat of cyberattacks. The court also found that SolarWinds was not obligated to update its risk disclosures following the cybersecurity incidents due to the uncertain significance of the incidents at the time.
- Other Public Statements: The court rejected the SEC’s securities fraud claims based on company-approved press releases, blog posts and podcasts. For example, a December 12, 2019, press release posted on the SolarWinds website promised commitment “to high security standards, which its partners rely on to help keep the systems they manage secure and compliant.” The court found this statement, and others, to be non-actionable puffery lacking the level of detail at which a reasonable investor would rely on them to make investment choices.
(2) False Filing Claims
The SEC brought false filing claims under Section 13(a) of the Exchange Act and Exchange Act Rules 12b-20, 13a-1, 13a-11 and 13a-13. These provisions require filing complete, accurate and timely reports to the SEC. To plead reporting violations, the SEC need not allege scienter.
The SEC alleged that SolarWinds’ Forms 8-K initially disclosing the SUNBURST attack were materially misleading because SolarWinds failed to disclose preceding cybersecurity incidents. The SEC argued that the language in the Forms 8-K was misleadingly theoretical; for example, the Form 8-K stated that the cybersecurity vulnerability, “if present and activated, could potentially allow an attacker to compromise” the SolarWinds platform. The SEC argued that the earlier cybersecurity incidents demonstrated that SolarWinds and its CISO allegedly knew that the cybersecurity vulnerability was no longer theoretical when the Forms 8-K were issued.
The court rejected this argument as to both SolarWinds and its CISO. The court emphasized the short time – two days – between discovery of the SUNBURST attack and the Form 8-K disclosures and took a more holistic, pragmatic approach to the ultimate message of the disclosures, finding that they “by any measure bluntly reported brutally bad news for SolarWinds,” based on what SolarWinds and its CISO knew when filing.
(3) Internal Controls Claims
The court rejected the SEC’s claims that SolarWinds violated both the internal accounting controls and disclosure controls provisions – provisions the SEC increasingly has employed in various settled actions, including actions involving cybersecurity incidents:
- Section 13(b)(2)(B): The SEC alleged that SolarWinds’ cybersecurity controls violated Section 13(b)(2)(B) of the Exchange Act. Section 13(b)(2)(B) requires that public companies “devise and maintain a system of internal accounting controls sufficient to provide reasonable assurances that … access to assets is permitted only in accordance with management’s general or specific authorization.”The court reasoned that Section 13(b)(2)(B) applies only to internal financial accounting controls and cannot be construed to cover cybersecurity controls. The court based its conclusion on (i) the plain meaning of “internal accounting controls,” finding that “a cybersecurity deficiency . . . cannot reasonably be termed an accounting problem”; (ii) the surrounding terms in Section 13(b)(2)(B), which refer to, inter alia, “transactions,” “preparation of financial statements,” “generally accepted accounting principles,” and ”books and records”; (iii) the lack of evidence of congressional intent that the provision reach cybersecurity controls; and (iv) that courts interpreting the provision consistently found it addresses financial accounting.The court rejected the SEC’s argument that it needs authority to regulate cybersecurity controls because deficiencies can expose a company’s core assets to damages or destruction. The court stated the SEC’s rationale “would have sweeping ramifications” and allow it to regulate everything from background checks used in hiring nighttime security guards to the lengths and configurations of computer passwords, which “cannot be squared with the statutory text.”
- Rule 13a-15(a): The SEC alleged that SolarWinds had ineffective disclosure controls in place in violation of Rule 13a-15(a) based primarily on the allegation that the company internally misclassified two earlier cybersecurity incidents. Rule 13a-15(a) requires public companies to maintain disclosure controls and procedures designed to ensure that information required to be disclosed in their SEC filings is recorded, processed, summarized and reported within specified time periods. The court held that the SEC did not plead a viable disclosure controls claim because (i) SolarWinds had a system of controls in place to facilitate the disclosure of potentially material cybersecurity risks and incidents and the SEC did not plead that there was any deficiency in the construction of this system; and (ii) the SEC did not adequately plead that two prior cybersecurity incidents were misclassified, as the company investigated both promptly and, based on the information available at the time, the company did not determine that it had been the victim of an incident affecting multiple customers.
Key Takeaways
The court’s decision offers varied lessons to be learned with respect to the future defense of cybersecurity events:
- Notably, the court rejected the SEC’s first-ever attempt to litigate an “internal accounting controls” claim under Section 13(b)(2)(B) of the Exchange Act for deficient cybersecurity controls. The ruling could undermine the SEC’s ongoing efforts to use internal controls as a “Swiss Army statute.” In recent years, the internal accounting provision has become a darling of SEC enforcement actions, given its perceived flexibility and lower state-of-mind threshold. Most recently, R.R. Donnelly agreed to pay more than $2 million to settle alleged disclosure and internal control failure violations relating to cybersecurity incidents and alerts. In rejecting the settlement, and others like it, dissenting SEC Commissioners observed that the SEC has used the internal accounting controls provision as “a multi-use tool handy for compelling companies to adopt and adhere to policies and procedures that the Commission deems good corporate practice.” Echoing this sentiment, the court rejected the SEC’s argument that it has authority to regulate cybersecurity controls simply because deficiencies can expose a company’s core assets to damages or destruction.
- The court also rejected the SEC’s effort to convert a handful of isolated process lapses into disclosure control violations. The court relied in significant part on the adequacy of a systemic cybersecurity disclosure process. Investment in the design and execution of internal cybersecurity reporting processes thus may overcome hindsight claims that a public company misjudged the significance of, and failed to disclose, cybersecurity incidents.
- The court dismissed the SEC’s claims that SolarWinds’ Form 8 K reporting in the aftermath of the cyberattack was misleading for failing to disclose prior cybersecurity incidents. This aspect of the decision provides some comfort to public companies issuing meaningful disclosures of cybersecurity events before not all information is known – a task made more challenging given the SEC’s new disclosure requirements.
- In a similar way, the decision limited the SEC’s ability to use otherwise tailored risk disclosures as a basis for securities fraud claims. The SEC attempted to argue that risk disclosures were incomplete because they failed to identify specific cybersecurity incidents that the SEC viewed as important in hindsight.
- Although the court rejected several of the SEC’s more aggressive arguments, the primary fraud claim against SolarWinds and its CISO survived. The court found that the SEC adequately pleaded securities fraud claims alleging that the Security Statement posted on SolarWinds’ website and disseminated to customers by the CISO misrepresented the company’s cybersecurity hygiene. SolarWinds was an early test case for individual actions. The failure to obtain outright dismissal means that CISOs and other officers remain exposed to future SEC actions and securities litigation.
Practical Considerations for Public Companies
The SolarWinds decision reinforces the wisdom of continued investment in policies and procedures surrounding cybersecurity reporting. Among other considerations:
- Public companies and CISOs still face significant risks. Despite the trimming of the SEC’s claims, the court found that a CISO involved in public statements can face exposure under the federal securities laws. CISOs need to understand their potential liability as officers and ensure that there are not discrepancies between concerns raised internally and statements made externally, particularly with respect to any such statements they approved or are made aware of. The SEC’s new regulations, past enforcement actions, and agency pronouncements are important guideposts for that evaluation.
- Practically speaking, public companies should align public disclosures of cybersecurity practices and incidents with board reporting, and board reporting with senior officer reporting. The SEC and private litigants seek to exploit gaps in the chain between front-line cybersecurity staff and public filings. Reasonably designed and executed disclosure controls should support that reporting chain.
- More specifically, when companies, particularly technology companies, make dedicated or prominent public statements about their cybersecurity practices, including website statements, they should consider an internal assessment to ensure that any public representations of specific cybersecurity practices (e.g., password and access controls, encryption, network monitoring and secure file sharing) align with internal practices and findings. Companies should work with counsel to evaluate whether to conduct the internal assessment under attorney-client privilege and how to document the assessment findings for use in potential investigations and litigation. Companies also should be aware that public disclosures about data security controls are likely to be scrutinized by other regulators, including the Federal Trade Commission and state attorneys general.
- Public companies should continue to draft tailored risk disclosures when possible, avoiding boilerplate that can be criticized in SEC investigations and private litigation. Issuers also should consider whether particular, significant events mean that the risk already has emerged and should be acknowledged.
- When a company prepares a Form 8-K disclosing a material cybersecurity incident, the company should ensure that the disclosure adequately describes the seriousness and scope of the incident. Although the court here found that it was not misleading for the company not to disclose prior related cybersecurity incidents, companies should consider the significance of any prior incidents. In July 2023, the SEC adopted rules and amendments that impose new cybersecurity-related disclosure requirements for public companies. Read our client alert, “SEC imposes new cybersecurity disclosure requirements,” for additional information on the new rules.
Whatever party emerges in the national election, we expect continued emphasis by the SEC in the cybersecurity space, which has been championed by both major parties and is considered vital to national security interests.

Was 2023 the Return of the Stark Law?
ARTICLE / REPORT
Was 2023 the Return of the Stark Law?
July 24, 2024
Read time: 2 min
The year 2023 was historic from a Stark Law enforcement perspective, as we witnessed a resurgence of False Claims Act (FCA) enforcement actions predicated on Stark Law violations. This increase was capped off in December 2023 by the largest-ever settlement predicated on alleged Stark Law violations in history. The 2023 enforcement actions primarily implicated physician compensation arrangements implemented by health systems and hospitals.
What lessons can be garnered for stakeholders in 2024 and beyond? This Special Report surveys several of the 2023 Stark Law enforcement actions and explains why, in light of recent regulatory developments, future complaints predicated on similar alleged conduct may be less likely or potentially, at least, more defensible. This Special Report then discusses key takeaways and compliance considerations gleaned from 2023 enforcement activity that may be useful to hospitals, health systems and other entities in tailoring their compliance plans. Finally, this Special Report offers several “best practice” recommendations for stakeholders to consider when developing physician compensation plans designed to expand their physician networks.

Pennsylvania Court Rejects Attempt to Block FTC Noncompete Ban
ARTICLE / CLIENT ALERT
Pennsylvania Court Rejects Attempt to Block FTC Noncompete Ban
July 24, 2024
Read time: 4 min
What Happened
On July 23, 2024, US District Court for the Eastern District of Pennsylvania declined to stay the September 4, 2024, effective date of the Federal Trade Commission’s (FTC) Final Rule that bans all new noncompete agreements nationwide and renders existing noncompete agreements binding most workers unenforceable. This ruling comes 20 days after a federal court in Texas – presented with the same legal arguments – preliminarily enjoined the FTC from enforcing the Final Rule against the parties in that case.
The Plaintiff Could Not Establish Irreperable Harm
The court found that the plaintiff – ATS Tree Services LLC (ATS) – failed to establish that it would suffer “irreparable harm” if the Final Rule went into effect and denied its motion for injunctive relief “[o]n that finding alone.”
Specifically, ATS’s proffered nonrecoverable costs of complying with the Final Rule and the “speculative” costs associated with “scal[ing] back its specialized training program to avoid losing its return on the investment of training its staff if it is unable to enforce its non-compete agreements” did not establish “irreparable harm.”
The Plaintiff Could Not Establish That the FTC Lacked the Authority to Issue the Final Rule
Even if ATS could establish “irreparable harm,” the court observed that ATS still could not prevail on its motion for injunctive relief because it could not establish the likelihood of success on the merits of its claim that the FTC lacked the authority to issue the Final Rule.
The court rejected ATS’s argument that the FTC lacks “substantive rulemaking authority” – as opposed to “procedural rulemaking” – under Section 6(g) of the FTC Act.
The court also rejected ATS’s alternative arguments that the Final Rule should be barred under (1) the “rule-of-reason” antitrust analysis that counsels against categorical prohibitions, (2) federalism principles, (3) the so-called “major questions doctrine” and (4) the nondelegation doctrine.
What About Other Noncompete Litigation?
This ruling sharply contrasts with the preliminary injunction ruling issued in Ryan LLC v. FTC on July 3, 2024, by the US District Court for the Northern District of Texas. That ruling provided that the plaintiffs were likely to succeed on the merits of their claim that the FTC lacks substantive rulemaking authority with respect to unfair methods of competition under the FTC Act. A final merits decision in Ryan LLC is expected by August 30, 2024.
Next Steps and Anticipated Litigation Strategies
The Final Rule is slated to go into effect on September 4, 2024. Companies not covered by an injunction issued by a federal judge will be subject to the Final Rule.
We anticipate that ATS will appeal this preliminary injunction ruling to the US Court of Appeals for the Third Circuit. We also anticipate that the parties in Ryan LLC v. FTC will prevail at the district court level and that the FTC will appeal the court’s final injunction decision to the US Court of Appeals for the Fifth Circuit. The outcome of these two cases at the federal court of appeals level – and likely others as more challenges are brought – will likely be reviewed by the US Supreme Court in the coming months.
Companies should stay informed about any updates or changes related to this case and the Final Rule’s effective date. In the meantime, companies should continue to consult with counsel to assess their existing use of noncompetes and other restrictive covenants to prepare for the Final Rule’s pending effective date and its implications. For any questions about the Final Rule, please contact your regular McDermott lawyer or one of the authors.

Google applicants? LAG Düsseldorf on admissibility & risk of damages
ARTICLE
Google applicants? LAG Düsseldorf on admissibility & risk of damages
July 23, 2024
Read time: 2 min
The HR News blog provides regular updates on recent developments in German employment law (in German).
In the latest HR NEWS article (German), Dr Philip Uecker gives an insight into the judgement of the LAG DÜsseldorf on background checks as a permissible part of the application process and the consequences for employers.
Visit the blog and/or register now for regular HR NEWS updates (in German).

Draft CCPA Regulations Stalled as Agency Struggles With Applicability of ADMT Rules
ARTICLE / CLIENT ALERT
Draft CCPA Regulations Stalled as Agency Struggles With Applicability of ADMT Rules
July 22, 2024
Read time: 5 min
On July 15, 2024, the California Privacy Protection Agency (CPPA) released proposed updates to the California Consumer Privacy Act (CCPA) regulations, including updates to the draft risk assessments, automated decisionmaking technology (ADMT), cybersecurity audits and insurance companies’ regulations. The CPPA board did not vote to send the revised proposals to final rulemaking during its July 16 meeting due to reservations about certain key concepts, such as the broad definition of ADMT. At this stage, the CCPA is unlikely to finalize the proposed rules this calendar year.
As we have written previously, these regulations will usher in significant operational changes for businesses. It is therefore prudent for companies to start preparing now and continue to monitor how the CPPA will tweak the rules around the edges.
General Updates to Existing Regulations
The latest draft regulations include several minor revisions to existing CCPA regulations, including the following:
- Recharacterizing the “right not to receive discriminatory treatment” as the “right not to be retaliated against and clarifying that this right also applies to applicants of educational programs, job applicants and students.
- Permitting companies to change the color of the alternative opt-out button to allow it to stand out on a webpage.
- Adding several examples to illustrate how to apply the rules, including ways a company can process data for internal purposes.
Automated Decisionmaking Technology Regulations
Top of mind for the CPPA drafters is the definition of ADMT. The proposed definition of ADMT is “any technology that processes personal information and uses computation to execute a decision, replace human decisionmaking, or substantially facilitate human decisionmaking.” Excluded from this definition are certain technologies like spreadsheets or databases, provided they are not substantially facilitating or replacing human decisionmaking.
The latest draft features an example scenario to try to cut through the definitional morass:
“For example, a business’s use of a spreadsheet to run regression analyses on its top-performing managers’ personal information to determine their common characteristics, and then to find co-occurrences of those characteristics among its more junior employees to identify which of them it will promote is a use of automated decisionmaking technology, because this use is replacing human decisionmaking. By contrast, a manager’s use of a spreadsheet to input junior employees’ performance evaluation scores from their managers and colleagues, and then calculate each employee’s final score that the manager will use to determine which of them will be promoted is not a use of automated decisionmaking technology, because the manager is using the spreadsheet merely to organize human decisionmakers’ evaluations.”
Although the example above is a step in the right direction, the ADMT definition still leaves much in the gray. Too much subjectivity and potential scope variance in the definition will undoubtedly lead to confused application and enforcement of the ADMT rules.
The draft regulations also include new privacy rights related to ADMT, which could create operational challenges for businesses; these include the rights to:
- Access ADMT, which would allow a consumer to access information about the business’s use of ADMT with respect to that consumer.
- Request to appeal ADMT, which would allow a consumer to appeal a significant decision made on the basis of ADMT.
- Opt out of ADMT, which would allow a consumer to opt out of the use of ADMT in limited circumstances.
Risk Assessments Regulations
As described in our previous article, the new regulations governing risk assessments require businesses to annually submit to the CPPA an abridged form of the business’s privacy risk assessment of any processing that “presents significant risk to consumers’ privacy.” The draft regulations revise the content requirements of the abridged risk assessments to include a plain-language explanation of the safeguards the business implemented or plans to implement to mitigate the negative impacts to a consumer’s privacy associated with the processing.
Cybersecurity Audits Regulations
The draft regulations propose limiting the requirements of cybersecurity audits in certain circumstances by removing the following from the December 2023 draft:
- The requirement that businesses assess and document in their cybersecurity audit how their cybersecurity program protects consumers from the negative impacts associated with data breaches.
- The option for businesses to annually submit a written acknowledgement that the business is not in full compliance with the cybersecurity audit rules. Instead, businesses may only annually submit a written certification that the business complied with the requirements.
Insurance Companies’ Regulations
As discussed in our previous client alert, “New cybersecurity, privacy, and automated decisionmaking rules coming soon to California,” the December 2023 draft regulations introduced new regulations applying to insurance companies. Those regulations clarified that insurance companies that meet the definition of “business” under the CCPA should comply with the CCPA with regard to any personal information not subject to the California Insurance Code. The new draft further clarified these requirements by adding several illustrative examples without materially changing how they apply.
What’s Next?
The CPPA board continues to debate the definition of ADMT and the resulting economic impact of this and other changes to the regulations. They have delayed finalizing the rules until at least September, which could mean that the rules could be finalized in early 2025 and come into effect later that summer.
If you have questions or need assistance with CCPA compliance or other state privacy laws, please contact any of the authors or your regular McDermott lawyer.
